 Umbilical cord blood transplantation is a curative procedure for patients with hematologic malignancies and genetic disorders and expands access to transplantation for non Caucasian patients unable to find a fully matched unrelated donor . In 2011 the US Food and Drug Administration required that unrelated UCBT be performed using either licensed UCB or unlicensed UCB under the Investigational New Drug program . The National Marrow Donor Program manages an IND under which 2456 patients underwent single or double UCBT between October 2011 and December 2016 . The median patient age was 31 years and 50 of children and 36 of adults were non Caucasian . The median time to neutrophil engraftment ie absolute neutrophil count 500 mm

@highlight Unlicensed umbilical cord blood units can be safely and effectively used for hematopoietic cell transplantation HCT in adult and pediatric patients.
@highlight Unlicensed umbilical cord blood expands access to racially ethnically diverse patients in need of HCT.
@highlight Further studies are required to compared licensed and unlicensed umbilical cord blood HCT.
